Ignite Creation Date:
2024-05-06 @ 3:05 PM
Last Modification Date:
2024-10-26 @ 1:42 PM
Study NCT ID:
NCT04518982
Status:
UNKNOWN
Last Update Posted:
2020-08-19
First Post:
2020-08-16
Brief Title:
Sintilimab and Lenalidomide as a Treatment for CAEBV
Sponsor:
Zhao Wang
Organization:
Beijing Friendship Hospital
Study Overview
Official Title:
Sintilimab and Lenalidomide as a Treatment for CAEBVa Multicenter Randomized Double-blind Placebo-controlled Clinical Trial
Status:
UNKNOWN
Status Verified Date:
2020-08
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a multi-center prospective randomized controlled clinical study to evaluate the effectiveness of a combination regimen of Sintilimab and lenalidomide in patients with chronic active EBV infection
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None